February 26 2021

vasopharm Appoints Chief Medical Officer

Prof John F. Stover, MD, PhD joins vasopharm management team

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced the appointment of Prof Dr John F. Stover as Chief Medical Officer. 

Prof Dr Stover has more than 25 years of global drug development experience in acute, chronic, and rare diseases having held clinical and pharmaceutical leadership functions. Before joining vasopharm, Prof Dr Stover held senior positions at Fresenius Kabi, Vifor Pharma, and Alexion Pharmaceuticals where he oversaw multiple clinical programs and contributed to the launch of different products internationally. Prof Dr Stover graduated in Medicine from the Johannes Gutenberg University Mainz, Germany. Prof Dr Stover is board certified in intensive care with extensive training in Switzerland, Germany, and United States of America. Prof. Dr Stover has a track record for clinical and experimental research in the area of neurotraumatology serving as Principal Investigator in different clinical trials, incl. the NOSTRA Phase II trial. In addition, he was a member of the Data Monitoring Committee for the NOSTRA Phase III trial.

Dr Andrew Clark, Chairman of vasopharm’s Board, commented:

“I am delighted that we have been able to recruit Prof Stover at such a momentous point in the development of Ronopterin. His extensive clinical experience in TBI, coupled with a deep understanding of the pharmacology of Ronopterin and its activity in patients, both in practice and as a DMC member, make him uniquely qualified to oversee the interaction with regulatory authorities. vasopharm will benefit significantly from his addition to the team as we look to provide physicians with a drug that can meaningfully impact the debilitating effects of acute TBI.”

Prof Dr Stover, newly appointed Chief Medical Officer, added:

“I am very enthusiastic about joining vasopharm, allowing me to continue my long-standing collaboration with a company dedicated to developing a novel treatment for patients with moderate and severe traumatic brain injury. It is fascinating to be at the verge of closing an existing gap by offering patients in need a new specific pharmacologic treatment.”

 

For further information, please contact: 

vasopharm GmbH
Christian Wandersee, CEO
Tel: +49-931-359099-0
Email: wandersee@vasopharm.com

 

NOTES TO EDITORS

About vasopharm GmbH
vasopharm is focused on the development of small molecule therapeutics which modulate the bioavailability of endogenous NO, by addressing the entire NO/cGMP signal cascade. vasopharm’s drug candidate Ronopterin represents a completely new type of NOS inhibitors targeting cerebral vessels and cerebral tissue. For Ronopterin, vasopharm received orphan drug designation for the treatment of moderate and severe TBI in Europe. 

 

 

back